Tixagevimab / cilgavimab (obligation for benefit assessment for the first time: COVID-19, pre-exposure prophylaxis for patients aged ≥ 12 years)

Subject:

• Active Substance: Tixagevimab / cilgavimab
• Name: Evusheld®
• Therapeutic area: COVID-19 disease
• Pharmaceutical company: AstraZeneca GmbH

Time table:

• Start: 15.05.2023
• Publication of assessment: 15.08.2023
• End of public hearing: 05.09.2023
• Final decision by G-BA: beginning of November 2023

Comparative therapy:

• Watchful waiting